Institutional Investor Files to Sell Over $2 Million in Protara Therapeutics Stock
Summary
An institutional investor, 667, L.P., affiliated with Baker Brothers Life Sciences, L.P., has filed a Form 144 indicating intent to sell 26,755 shares of Protara Therapeutics common stock, part of a larger combined sale totaling 348,794 shares.
Key Events
-
Intent to Sell Shares
667, L.P., an institutional investor and former affiliate, filed a Form 144 to sell 26,755 shares of common stock, valued at approximately $161,584.
-
Coordinated Institutional Sale
This sale is part of a larger, coordinated disposition by Baker Brothers entities, totaling 348,794 shares with an estimated aggregate market value exceeding $2 million.
-
Acquired in Public Offering
The shares were acquired in an underwritten public offering on December 8, 2025.
Analysis
This Form 144 indicates that 667, L.P., an entity affiliated with Baker Brothers Life Sciences, L.P., intends to sell 26,755 shares of Protara Therapeutics common stock, valued at approximately $161,584. This sale is part of a larger, coordinated disposition by Baker Brothers entities, which collectively intend to sell 348,794 shares with an estimated aggregate market value exceeding $2 million. While the individual filing is modest, the combined sale by a significant institutional investor and former affiliate suggests a reduction in their stake, which could be perceived negatively by the market. Investors should monitor the actual execution of these sales and any further disclosures from Baker Brothers.
At the time of this filing, TARA was trading at $5.49 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $282.4M. The 52-week trading range was $2.77 to $7.82. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.